Innovent Biologics Inc (6IB) — Capital Reinvestment Ratio
Innovent Biologics Inc (6IB) has a Capital Reinvestment Ratio of 0.97x as of December 2020, meaning it reinvests 1% of its operating cash flow (€217.96 Million) in capital expenditures (€211.14 Million). See Innovent Biologics Inc balance sheet quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Innovent Biologics Inc Capital Reinvestment Ratio (2023–2025)
This chart tracks Innovent Biologics Inc's Capital Reinvestment Ratio across 3 annual periods. Check Innovent Biologics Inc (6IB) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Innovent Biologics Inc (2023–2025)
Year-by-year Capital Reinvestment Ratio for Innovent Biologics Inc from 2023 to 2025. For live market cap and broader valuation context, see 6IB market cap overview.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.07x | €10.00 Billion | €683.27 Million | ▼ -94.8% |
| 2024 | 1.33x | €1.29 Billion | €1.71 Billion | ▼ -85.8% |
| 2023 | 9.36x | €147.81 Million | €1.38 Billion | — |